In vitro activity of a new 'higher-lactam' antibacterial agent LY 193239.
In vitro activity of the new bicyclic pyrazolidinone LY 193239 (Eli Lilly) was evaluated against 52 clinical isolates of Haemophilus influenzae (4 were beta-lactamase producers), 32 Enterococcus faecalis, 14 Neisseria gonorrhoeae (1 beta-lactamase-positive) and 19 Neisseria meningitidis. Activity was best against Neisseria spp. and H. influenzae, including penicillinase-producing strains. Results of the time-kill study against a non-enzyme-mediated penicillin resistant strain of N. meningitidis indicate that exposure to an antibacterial concentration four times the minimal inhibitory concentration was bactericidal. E. faecalis was insensitive.
Botha
P L
PL
Department of Medical Microbiology, University of the Orange Free State, Bloemfontein, OFS.
Vorster
E
E
Jordaan
C
C
D001419:Bacteria / Q000187:drug effects*; D004352:Drug Resistance, Microbial; D006193:Haemophilus influenzae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D011720:Pyrazoles / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
D011720:Pyrazoles; D013844:Thiazoles; C068345:LY 193239